Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24¿weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group Academic Article 2023 uri icon

authors

  • Berenguer-Ruiz S
  • Carretero-Hernández G
  • Mateu-Puchades A
  • Ferran M
  • Del Alcázar E
  • Santos-Alarcón S
  • de Aranibar FJG
  • BELINCHON ROMERO, ISABEL
  • González-Cantero Á
  • Ruíz-Genao D
  • Eiris-Salvado N
  • Aparicio-Domínguez M
  • Rocamora-Durán V
  • Rivera-Diaz R
  • de la Cueva P
  • Daudén E
  • Salgado-Boquete L
  • Llamas-Velasco M
  • Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology
  • Herranz-Pinto P
  • Ruíz-Villaverde R
  • López- Ferrer A
  • Santos-Juanes J
  • Fernández-Freire LR
  • Hospital-Gil M
  • Arias-Santiago S

publication date

  • 2023